You are here

Candida: Anti-fungal target and immunotherapeutic candidate

Invention Number: 
501_1863
Candidalysin represents a very promising new therapeutic target to treat C. albicans infections, overcoming resistance to existing anti-fungals. As a vaccine candidate it can be delivered via a number of routes; oral or vaginal delivery to elicit mucosal immunity and i.v. or i.p. delivery for systemic protection. Antibodies against candidalysin might be used therapeutically to produce passive immunity and the peptide may be a drug target for development of new anti-fungal agents.

The Problem

Candida albicans is an opportunistic fungal pathogen, which normally exists as a commensal of the oral cavity and gastrointestinal tracts and frequently causes of superficial vaginitis infections. Moreover, common clinical procedures, such as gastrointestinal surgery, implantation of a central venous catheter or antibiotic treatment are major risk factors for life-threatening systemic candidiasis. 

Systemic candidiasis is now the third most common cause of hospital-acquired bloodstream infections and is often fatal, having 30–50% mortality which equates to ~100,000 deaths/year. Damage of host cells and uncontrolled immune activation are the hallmarks of several diseases caused by C. albicans. In the USA, yearly healthcare costs for fungal infections are $3 billion, of which Candida infections account for $2 billion. EU healthcare costs are estimated to be similar. Therefore, Candida pathogens carry an immense health burden and represent a major socio-economic challenge for worldwide communities.

The Solution

It is known that expression of the Candida gene ECE1 (extent of cell elongation 1) is upregulated during hypha formation and that the gene’s product, Ece1, can be proteolytically processed by Kex2 into eight peptide fragments. 

The inventors have now found that a single 32 amino acid proteolytic fragment of Ece1 (termed Candidalysin) acts both as a novel peptide pore-forming toxin and as an immunostimulant. No truncations have been found that produce cell lysis or inflammatory responses in epithelial cells, although the fragment’s carboxy-terminal KR residues appear to be important for membrane interactions and damage induction, but not its immunostimulatory function. This opens a possible therapeutic window in which protective immunity may be generated without triggering damage.  

To conclude, neutralisation of Candidalysin has the strong potential to prevent not only host damage during C. albicans infections but also deleterious inflammatory responses. Data obtained using multiple approaches supports the fragment representing a very promising new therapeutic target to treat C. albicans infections. Additionally, a modified fragment can form the basis of an antigen or adjuvant to provide mucosal protection against C. albicans and related infectious agents. Finally a range of diagnostic applications for antibodies against Candidalysin are possible.

Benefits

Candidalysin represents a very promising new therapeutic target to treat C. albicans infections, overcoming growing resistance to existing anti-fungals. As a vaccine candidate peptide 3 can be delivered via a number of routes; oral or vaginal delivery would be favoured if mucosal immunity was required and intravenous or intraperitoneal delivery might be preferred for systemic protection. Additionally, antibodies against the peptide might be used therapeutically to produce passive immunity. Application may be topical or, in the case or septicaemia, systemic.

Peptides_Kings College_UNSW

Opportunity

We are seeking development partners wishing to take options / evaluation licences over the technology. Exclusivity in specified fields could be available for a suitable partner.

IP Status

Pending in the European, Chinese and US patent offices, taking priority from an earlier GB filing. The Joint Applicants are King’s College London, UK and Hans-Knöll Institut, Jena, DE. (US application number: 14/783,237; Priority date: 11 April 2013)  

scanning electron microscopy_Kings College_UNSW

References

See Nature, 7 April 2016, vol. 532, pp 64-68, with News & Views item on pp 41-42 of the same issue.

Contact

Dr Ceri J. Mathews
IP & Licensing Manager
King’s College London
Email: ceri.mathews@kcl.ac.uk